Dr. Thomas Seyfried Cancer Protocol: Press-Pulse Therapy, Ketogenic Diet & 2026 Clinical Evidence

By Editorial Team July 23, 2026

Quick Answer

Dr. Thomas Seyfried, a biologist at Boston College, argues that cancer is primarily a mitochondrial metabolic disease rather than a genetic one. His core treatment framework — the Press-Pulse protocol — pairs a therapeutic ketogenic diet that restricts glucose and glutamine (the "press") with pulsed adjuncts like glutaminase-inhibiting drugs, hyperbaric oxygen, or fasting (the "pulse"). Mechanistic and preclinical evidence is strong; human evidence is a mix of promising case reports and small, mostly inconclusive trials — including a 2026 randomized pancreatic cancer trial that showed a survival trend without reaching statistical significance. Most integrative oncologists treat metabolic therapy as a physician-supervised adjunct to, not a replacement for, standard cancer care.

Executive Summary: Who Is Thomas Seyfried?

Thomas N. Seyfried, Professor of Biology at Boston College, is best known for a metabolic model of cancer that challenges the field's dominant genetic explanation. Rather than treating cancer primarily as a disease of gene mutations, Seyfried frames it as a disease of dysfunctional cellular energy production — damaged mitochondria that force cells to rely on fermentation of glucose and glutamine instead of normal oxidative respiration. The framework builds on, and substantially extends, the historical Warburg effect.

A 2026 population study in Nature Communications found that machine-learning-predicted insulin resistance was associated with a higher risk of 12 cancer types among nearly 500,000 UK Biobank participants — evidence, proponents argue, that metabolic dysfunction is not just a bystander in cancer but a modifiable axis of disease. As of mid-2026, Seyfried continues to publish and lecture actively on mitochondrial metabolic theory from his position at Boston College.

The Case Against Standard-of-Care Statistics

Seyfried is openly critical of conventional cancer treatment. In Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer, he argues that most oncologists are effectively required to offer chemotherapy and radiation as first-line options — regardless of toxicity — partly because departing from standard protocols can carry professional and legal risk for the treating physician.

The mortality figures he and others cite are real, though they need context. A 2025 study in BMC Cancer found 30-day mortality after systemic anti-cancer therapy of roughly 7%, rising to an estimated 15–18% when chemotherapy was combined with immunotherapy. Separately, a frequently cited Australian analysis estimated that cytotoxic chemotherapy's independent contribution to 5-year survival across adult solid tumors averaged around 2.3% in Australia and 2.1% in the USA (Morgan et al., 2004).

Important context: that 2004 figure is an average across all adult solid tumors and all stages combined — it is frequently misused online as if it applied to every cancer type or every patient. For chemo-sensitive cancers (testicular cancer, many lymphomas, some leukemias), chemotherapy's survival contribution is far higher than the population average; for others it is lower. Treat single aggregate statistics like this as a starting point for a conversation with an oncologist, not a verdict on any individual's own treatment plan.

Seyfried's own framing is blunter: he has argued that chemotherapy functions, in effect, as a mitochondrial poison, and that cancer cells are ordinary cells that lost normal mitochondrial function after exposure to carcinogens, radiation, chronic inflammation, or viral damage — leaving them unable to repair themselves and prone to uncontrolled growth. Related: Metabolic Therapy for Cancer — 113+ Case Reports (2026 Edition)

Diet and Cancer: Why Food Isn't Neutral

One of the first questions many people ask after a cancer diagnosis is deceptively simple: "What should I eat?" Too often the answer is some version of "it doesn't matter — eat whatever makes you happy." That response reflects a narrow view of nutrition. Every meal supplies not just calories but biochemical signals that influence insulin, inflammation, and the fuel available to a tumor (Marik, 2026). Dietary choices are not an afterthought to cancer therapy — in the metabolic framework, they are foundational.

Cutting Off Cancer's Fuel Supply: The Ketogenic Diet

Cancer cells commonly obtain up to 95% of their energy from glucose and glutamine via glycolysis and the Krebs cycle. The logic of metabolic therapy is straightforward: if a tumor depends on two specific fuels, restricting both may slow it down. The dietary tool for doing this is the ketogenic diet — very low in carbohydrates, moderate in protein, and high in fat, driving the body into ketosis. Healthy cells adapt readily to ketone bodies and fatty acids as fuel; Seyfried's argument is that cancer cells, with their damaged mitochondria, cannot make the same switch.

Ketogenic diet mechanism for starving cancer cells of glucose and glutamine

Glioblastoma is the tumor type most often cited as responding to a ketogenic diet. Seyfried's own summary of the mechanism: no tumor cell, in his view, can survive the simultaneous absence of glucose and glutamine, particularly once ketone bodies are supporting the viability of surrounding normal cells.

Ketogenic diet and cancer metabolism diagram

A Cautionary Data Point: Carbohydrate Intake and Mortality

A prospective cohort of 414 head-and-neck cancer patients found that higher carbohydrate intake was associated with roughly double the risk of death — hazard ratios of 2.29 for all-cause mortality and 2.45 for cancer-specific mortality — challenging the common advice to "eat whatever helps you gain weight" during treatment (PubMed, 2019). [Evidence tier: 2b — single prospective cohort study]

Fasting and Calorie Restriction

Seyfried has suggested that the fastest route into deep therapeutic ketosis is a medically supervised 3–5 day water-only fast. A 2022 review in Cancer Science supports the underlying mechanism, noting that fasting can limit cancer cells' adaptability and growth while potentially increasing the effectiveness of concurrent treatment and reducing adverse events. [Evidence tier: 5 — narrative review of mechanistic and preclinical data]

For most people, a multi-day water fast is impractical without close medical supervision. A gentler entry point is time-restricted eating — compressing meals into a shorter daily window, for example finishing dinner by 6 p.m. and delaying the first meal until noon the next day (an 18-hour fasting window). Content creators such as Dr. Eric Berg have popularized this approach alongside a ketogenic diet as a way to shift metabolic gene expression:

The Press-Pulse Protocol Explained

Seyfried and colleagues formalized their metabolic strategy as "Press-Pulse" therapy (Seyfried et al., Nutrition & Metabolism, 2017; Frontiers in Nutrition, 2020), borrowing a term from paleobiology describing how chronic ("press") and acute ("pulse") stressors together can collapse a population more effectively than either alone. Applied to cancer:

The Press: a sustained ketogenic diet, keeping the blood Glucose-Ketone Index (GKI) in a targeted therapeutic range, creates chronic metabolic stress on tumor energy metabolism system-wide — wherever the cancer is located in the body.
The Pulse: intermittent, targeted stressors layered on top of the press — glutaminase-inhibiting drugs, hyperbaric oxygen therapy (HBOT), intravenous vitamin C, or in some protocols conventional chemotherapy or radiation at reduced, "metabolically supported" doses — strike the already-weakened cancer cells.

Because cancer cells have impaired mitochondrial oxidative phosphorylation, the theory holds that they cannot metabolize ketone bodies for energy the way healthy cells can (Nature, 2019) — so a diet that lowers blood glucose while raising ketones is intended to starve the tumor while sparing normal tissue.

Stress management is the protocol's less-discussed third leg. Seyfried has argued that the psychological shock of a cancer diagnosis, and the chronic stress that can follow it, raises cortisol and blood glucose in ways that may work against the dietary "press" — making sleep, emotional support, and stress reduction a functional part of the strategy rather than an optional add-on.

Safety note: a strict, long-term ketogenic diet built on poor-quality fats (high omega-6 vegetable oils, processed meats) carries its own risks, including reported cases of fatty liver and lipid abnormalities. Fat quality — favoring olive oil, avocado, fatty fish, and pasture-raised animal fats over industrial seed oils — matters as much as the macronutrient ratio itself. This diet should be undertaken with physician and dietitian supervision, especially during active cancer treatment.

Case Reports and Clinical Evidence (Reference Table)

Rather than narrating each case report in prose, here is the published human evidence consolidated into one scannable table, graded by evidence tier. Case reports (tier 4) are useful for generating hypotheses but cannot establish that a treatment caused an outcome — there is no control group, and publication bias favors dramatic successes over the far more common non-responses.

Patient	Diagnosis	Regimen	Follow-Up	Outcome	Tier	Source
47F	Stage IV (T4N3M1) breast cancer, multi-organ mets	MSCT + ketogenic diet + hyperthermia + HBOT (6 mo)	2 years	Complete, durable response	4	Cureus, 2021
38M	Glioblastoma multiforme	Ketogenic diet (20 mo) + chemoradiation	20 months	Tumor reduced ~1.5cm; no clinical deficits	4	Front. Nutr., 2018
29F	Stage IV triple-negative breast cancer	MSCT + KD + HT + HBOT (6 mo)	16 months to mastectomy	Complete pathological response	4	Cureus, 2017
54M	Lung cancer with brain metastases	Ketogenic diet after failed chemo/radiation	9 years	Brain and lung tumors stable in size	4	Cureus, 2022
45F	Breast cancer, widespread visceral/bone/brain mets; <1 month prognosis given	Press-Pulse therapy from Nov. 2018	~2.5 years	Stable, no recurrence, improved QoL at last scan	4	Case report, 2021
n=80	Locally advanced / metastatic breast cancer	Randomized: ketogenic diet vs. control, 12 weeks	12 weeks	Lower serum insulin; tumor shrinkage in KD arm	1b/2b	Clin. Nutr., 2021
n=32	Metastatic pancreatic cancer	Randomized: chemo + medically-supervised KD vs. chemo alone	Phase II, 2026	Survival trend favoring KD arm; not statistically significant	1b	Cancer, 2026 (Jameson et al.)
Cohort	Newly diagnosed glioblastoma	3:1 ketogenic diet + standard-of-care chemoradiation, 16 weeks	16 weeks	Safe/feasible; improved QoL and mood; radiographic response in some	2b/3	Sci. Reports, 2025

MSCT = metabolically supported chemotherapy; HT = hyperthermia; HBOT = hyperbaric oxygen therapy; KD = ketogenic diet; QoL = quality of life. See evidence-grading section for tier definitions.

2026 Clinical Trial Update

Three developments since our last review are worth flagging for anyone tracking this space closely:

1. The First Randomized Trial of Keto + Chemo Reports Survival Data

In February 2026, Cancer published the first randomized phase II trial testing a medically supervised ketogenic diet alongside standard chemotherapy (gemcitabine, nab-paclitaxel, and cisplatin) in 32 patients with metastatic pancreatic cancer (Jameson et al., 2026). Patients following the diet — delivered through a structured program with biomarker tracking and continuous coaching — showed a survival trend favoring the ketogenic-diet arm, though the trial was small and not powered to reach statistical significance. It is nonetheless the most rigorous prospective test of the "diet as adjunct" hypothesis published to date. A companion commentary in the same journal (Bruckner & Knopf, 2026) cautions that real-world dietary trials face major design challenges — adherence tracking, prognostic confounding by baseline nutritional status, and small sample sizes — that limit how confidently results can be generalized.

2. Glutaminase Inhibition Research Has Matured Past DON

A comprehensive July 2026 review in Pharmaceutics, "70 Years of DON and Beyond", traces the field from DON's original toxicity problems through newer, better-tolerated glutaminase-targeting strategies now being tested as part of combination regimens rather than standalone therapy. The most advanced successor compound, DRP-104, is a tumor-targeted prodrug designed to release its active glutamine-antagonist payload selectively inside tumor tissue, sparing normal cells the toxicity that limited DON. DRP-104 is currently in early-phase human trials (NCT04471415) for advanced solid tumors, both alone and combined with immunotherapy.

3. Keto-Diet-Plus-Immunotherapy Trials Are Now Recruiting

Two active trials are testing whether a ketogenic diet can improve response to immune checkpoint inhibitors: a Phase I study at Ohio State University Comprehensive Cancer Center in metastatic melanoma and kidney cancer (NCT06391099, estimated completion 2027), and a trial at Rabin Medical Center in Israel covering melanoma, cutaneous squamous cell carcinoma, and renal cell carcinoma using an intermittent "2 weeks on, 1 week off" ketogenic schedule (NCT06896552). Separately, a 2025 clinical study in glioblastoma patients following dietary ketogenic metabolic therapy reported favorable responses in a case-series format (Kiryttopoulos et al., Frontiers in Nutrition, 2025). [Evidence tier: 3b/4 — uncontrolled clinical case series]

Taken together, these updates don't settle the debate — but they mark a shift from case reports and mouse models toward properly designed human trials, which is exactly what critics of the metabolic-cancer field have been asking for.

Warburg, Fatty Acid Oxidation, and Metabolic Flexibility

A more nuanced picture has emerged in recent years: many tumors don't rely on a single metabolic pathway. Depending on tumor type, microenvironment, and stage, cancer cells can generate ATP through glycolysis, oxidative phosphorylation, fatty acid oxidation, and glutamine metabolism — sometimes simultaneously. Rather than being locked into pure fermentation, cancer cells are often metabolically flexible, adapting fuel use to whatever is available.

Seyfried's rebuttal to this critique is narrower than his critics sometimes suggest: he argues specifically that cancer cells cannot sustain themselves through oxidative phosphorylation alone — they always require some contribution from glucose and glutamine fermentation, even when other pathways are also active (Marik, summarizing Seyfried).

Could the Metabolic Approach Be Wrong?

Responsible reporting on this topic means giving equal weight to the evidence that complicates the picture. Several credible sources do.

The systematic reviews are more cautious than the case reports

A 2021 systematic review of 39 studies concluded that clinical evidence for ketogenic diets' effectiveness in cancer patients was still lacking. A larger 2024 review of 252 randomized controlled trials reached a similarly cautious conclusion about dietary interventions generally in cancer care. A 2024 commentary in the Journal of the National Cancer Institute pushed back on that second review, arguing it did not adequately account for behavioral engagement or risk of bias, and noted that weight management alone is independently associated with better outcomes in breast and prostate cancer — meaning well-designed trials, not the absence of a signal, may be what's missing (JNCI, 2024).

The diet itself is not risk-free long-term

A 2024 review in Current Problems in Cardiology concluded that the ketogenic diet does not meet standard criteria for a "healthy diet" when followed indefinitely, citing evidence of lean muscle mass loss without a clear body-composition advantage over balanced diets in some comparisons (Curr. Probl. Cardiol., 2024).

Two more recent studies add texture to this concern. A 2026 mouse study in the Journal of Nutrition found that ketogenic and high-fat diets produced rapid weight gain, elevated blood sugar, and measurable liver damage compared with a high-carbohydrate diet at matched calorie intake — meaning the effect came from macronutrient composition, not calories. A separate 2025 study in Cell found that high-fat feeding altered mitochondrial and oxidative-stress signaling in ways that differed meaningfully between male and female subjects, a reminder that sex-specific metabolic responses are still poorly understood in this research area.

A prominent low-carb advocate changed his position

Dr. Joseph Mercola, who spent years promoting a low-carbohydrate ketogenic approach and authored a bestselling book advocating it, has since publicly revised his stance after encountering Ray Peat's bioenergetic model of metabolism. Mercola now argues that chronic very-low-carbohydrate eating can itself become a metabolic stressor — he has written that he currently consumes roughly 500 grams of carbohydrate per day, mostly from rice and ripe fruit, and considers this more supportive of long-term mitochondrial energy production than his earlier low-carb regimen. He has also written that nearly every chronic disease, in his current view, traces back to impaired mitochondrial energy production rather than carbohydrate intake itself — the opposite emphasis of where he started. His reversal doesn't settle the science, but it's a useful reminder that even committed low-carb advocates disagree on how far to take dietary carbohydrate restriction, and for how long.

A large Japanese cohort found the opposite of a one-size-fits-all answer

A 2023 study in The Journal of Nutrition, led by Dr. Takashi Tamura at Nagoya University, found that men with low carbohydrate consumption and women with high carbohydrate consumption both faced elevated risk of overall and cancer-related death — suggesting the healthiest pattern may be sex-specific and moderate rather than extreme in either direction (J. Nutr., 2023).

Refined sugars — added sugars and high-fructose corn syrup in ultra-processed foods — are consistently linked to worse metabolic and cancer outcomes; intrinsic sugars from whole fruit, delivered with fiber and micronutrients, behave differently in the body. The reasonable middle ground most clinicians land on: minimize ultra-processed carbohydrates and added sugar for everyone, but treat strict long-term carbohydrate restriction as an individualized, supervised decision rather than a universal prescription.

L-Glutamine, DON, and Glutaminase Inhibition

Seyfried's key addition to the classical Warburg effect is glutamine. Damaged mitochondria — with disorganized, defective cristae — leave cancer cells unable to generate energy through normal oxidative respiration, so they lean on fermentation of both glucose and the amino acid glutamine. Seyfried has put it plainly: cancer cells "cannot breathe," but they also cannot survive without sugar and glutamine. He further argues that the reactive oxygen species generated by damaged mitochondria — not inherited mutations — are the primary drivers of the genetic changes seen in tumors, making mutation an effect of metabolic damage rather than its cause. This remains one of the more contested claims in his framework; mainstream oncology still treats driver mutations as causally important in most cancers.

Targeting glutamine metabolism directly is not new. DON (6-diazo-5-oxo-L-norleucine), first studied roughly 70 years ago, was the original glutaminase-blocking compound but was abandoned clinically due to severe gastrointestinal toxicity. As covered in the 2026 update above, that toxicity problem is what newer tumor-targeted prodrugs like DRP-104 are specifically designed to solve.

Among natural compounds, EGCG from green tea is among the best-studied glutamine-metabolism inhibitors, targeting glutamate dehydrogenase — the enzyme that converts glutamate into α-ketoglutarate during glutaminolysis (Hope, 2025). Preliminary research also points to berberine as promising for glutamine-driven tumors, pending better delivery methods to overcome its poor bioavailability (Onco, 2025).

Metabolic flexibility matters here too: cycling between carbohydrate-rich and fat-based fuel periods — through time-restricted eating, occasional low-carb days, or supervised fasting — may help keep cellular metabolism adaptable rather than rigid. Persistently high blood sugar and chronic low-grade inflammation from ultra-processed food and refined sugar work against that flexibility and are independently linked to tumor-permissive conditions (Jhaveri, cited in Epoch Times).

PET Scans and Glucose

PET scan showing glucose (FDG) uptake used to visualize cancer metabolic activity

A PET scan works by injecting a radioactive glucose analog, FDG (18F-fluorodeoxyglucose), which active cells take up and metabolize. Because rapidly dividing cancer cells often consume disproportionate amounts of glucose, they appear as bright "hot spots" on the resulting scan — the same glucose-hungry behavior that underlies Seyfried's entire treatment rationale (Stanford Medicine). One important caveat noted by critics: not all cancers show this pattern strongly. Prostate cancer, for instance, is notoriously difficult to image with standard FDG-PET precisely because it doesn't rely on glucose fermentation to the same degree — a reminder that the Warburg/glutamine model fits some cancers far better than others.

The Carb Question: One Size Doesn't Fit All

Some clinicians argue that the traditional "simple vs. complex carbohydrate" framework misses an important variable: individual gut health. In this view, someone with a compromised gut microbiome may tolerate easily digestible simple carbohydrates better than fiber-heavy complex carbs, which can feed gas-producing bacteria and worsen symptoms in a damaged gut — with a gradual, supervised transition back toward complex carbohydrates as gut and metabolic health improve. This is a specialized, individualized protocol rather than a general recommendation, and it should be undertaken with a knowledgeable practitioner rather than self-directed — the specific reintroduction steps involved (including short-term use of simple sugar sources to stabilize a severely compromised gut) can do harm if mistimed. [Evidence tier: 5 — clinical framework, not a controlled trial]

Clinicians Using Press-Pulse Principles in the US

Full adoption of the formal Press-Pulse protocol by board-certified oncologists remains rare — the approach is still considered experimental within mainstream oncology. That said, several US-based integrative practitioners incorporate ketogenic metabolic therapy, glucose restriction, and metabolic targeting that overlap substantially with Seyfried's framework, and some cite his work directly. As always, verify current credentials, availability, and whether a practice is accepting new patients directly with the clinic before reaching out.

Dr. Dawn Lemanne, MD — Oregon Integrative Oncology, Ashland, OR. Board-certified medical oncologist (Stanford-trained) using personalized ketogenic diets for tumor types including brain cancers, with GKI monitoring during radiation/chemo. oregonio.com
Root Causes MD (Drs. Nasha Winters, Paul Anderson, Neil McKinney) — Fort Myers, FL. Metabolic-oncology-focused naturopathic practice explicitly referencing Seyfried's glucose-fermentation model; combines ketogenic/low-carb protocols with hyperthermia, IV nutrients, and mistletoe therapy. rtcausesmd.com
Dr. Ian D. Bier, ND, PhD, FABNO — Human Nature Natural Health, Portsmouth, NH. Combines ketogenic metabolic therapy with hyperbaric oxygen for metastatic cancers. humannaturenaturalhealth.com
Dr. Mel Schottenstein, NMD — Mitogenesis, Scottsdale, AZ. Personalized metabolic plans targeting mitochondrial dysfunction, citing Seyfried's theory directly. mitogenesis.health
Additional resources: Dr. Amanda King, ND · Find Integrative Oncologists directory · Consult a healthcare provider virtually

What is GKI? The Glucose-Ketone Index is the ratio of blood glucose to blood ketones, used as a marker of ketosis depth. Lower GKI indicates deeper therapeutic ketosis; practitioners working with cancer patients often target specific ranges based on tumor type and treatment goals (patient.info).

How We Grade the Evidence (CEBM)

Throughout this guide, evidence is tagged using the Oxford Centre for Evidence-Based Medicine (CEBM) hierarchy, from strongest to weakest:

Tier	Evidence Type
1a	Systematic review of randomized controlled trials
1b	Individual randomized controlled trial
2a/2b	Systematic review of cohort studies / individual cohort study
3a/3b	Systematic review of case-control studies / individual case-control study
4	Case series or case reports (no control group)
5	Expert opinion or mechanistic/preclinical reasoning without critical appraisal

A Practical Cancer-Prevention Protocol

Asked how an average person can protect mitochondrial health and reduce cancer risk, Seyfried points to periodic fasting, a lower-carbohydrate diet emphasizing whole foods, and regular exercise — and has been blunt about ultra-processed "Western diet" patterns being linked not just to cancer but to Alzheimer's, type 2 diabetes, and obesity. A 2023 umbrella review in the BMJ found that the highest sugar-sweetened-beverage intake was associated with a doubling of hepatocellular carcinoma risk compared with the lowest, and that each 25g/day of fructose intake was linearly associated with a 22% higher risk of pancreatic cancer.

No single intervention prevents cancer. A layered, individualized approach tends to perform better than any one silver bullet:

Build the base with whole foods: a plant-forward diet rich in colorful vegetables and fruit, with Mediterranean-style patterns as a reasonable template.
Limit the obvious harms: ultra-processed food, sugary drinks, refined grains, excess processed/red meat, smoking, and alcohol.
Consider evidence-based supplementation, individualized and discussed with a physician:
- Vitamin D3: ~2,000 IU/day, adjusted to blood level, ideally with K2 and magnesium (Frontiers in Aging, 2022)
- Omega-3 fatty acids: ~1g/day
- Bioavailable curcumin: ~500mg/day
- Green tea catechins (EGCG): ~500mg/day, taken with food
- Enhanced-absorption berberine: ~500mg/day, primarily relevant for those who are overweight
Move daily: a mix of moderate aerobic activity, strength, and resistance training, roughly 30 minutes/day.
Protect sleep and manage stress: both are central to immune function, not peripheral to it.
Reduce environmental toxin exposure where practical.

A 2026 conceptual framework proposes going further with a seven-layer metabolic intervention model, integrating dietary modulation, repurposed drugs (ivermectin, mebendazole), mitochondrial-targeting agents like metformin, anti-inflammatory nutraceuticals, cancer stem cell targeting, immune-metabolic support, and lifestyle change. For a broader index of cancer-specific causes, screening, and treatment resources, see the cancer resource hub. Whatever stage you're at — newly diagnosed, in recovery, or focused on prevention — consult your healthcare provider before making changes to an active treatment plan.

Frequently Asked Questions

Is Thomas Seyfried's metabolic theory of cancer accepted by mainstream oncology?

Not as a replacement for the genetic model. Mainstream oncology views cancer as driven primarily by accumulated genetic mutations, with metabolic changes as a downstream consequence. Seyfried's view — that metabolic dysfunction is the primary driver and mutations are largely a downstream effect — remains a minority position, though metabolic vulnerabilities are increasingly studied as a legitimate adjunct target rather than dismissed outright.

Can a ketogenic diet cure cancer on its own?

No credible evidence supports the ketogenic diet as a standalone cure. The strongest human data — including the 2026 randomized pancreatic cancer trial — test it as an adjunct alongside chemotherapy, not a replacement for it. Case reports describing dramatic standalone responses exist but are uncontrolled and cannot rule out other contributing factors.

What is the Press-Pulse protocol in simple terms?

It's a two-part strategy: a sustained ketogenic diet creates constant ("press") metabolic pressure on a tumor by limiting glucose and glutamine, while intermittent, targeted treatments — drugs, hyperbaric oxygen, or reduced-dose conventional therapy — deliver acute ("pulse") strikes against the weakened cancer cells.

Is a strict ketogenic diet safe to follow long-term?

It depends on fat quality, individual metabolic health, and supervision. Long-term strict ketogenic diets built on poor-quality fats have been associated with lipid abnormalities and, in some reports, liver strain. Most integrative oncologists recommend it as a time-limited, monitored intervention rather than a lifelong default — and stress fat quality (olive oil, fish, avocado) over quantity alone.

What is the Glucose-Ketone Index (GKI) and why does it matter?

GKI is the ratio of blood glucose to blood ketones, used to gauge how deep a person's ketosis is. Practitioners using metabolic therapy for cancer typically monitor GKI regularly and adjust diet or fasting to hit a target range appropriate to the tumor type and treatment phase, rather than relying on ketone levels alone.

Should someone stop chemotherapy or radiation to try metabolic therapy instead?

No practitioner cited in this guide — including those who use ketogenic protocols most extensively — recommends abandoning standard oncologic care in favor of diet alone. The evidence base supports metabolic therapy as an adjunct under medical supervision, not a substitute. Decisions about stopping or modifying active cancer treatment should be made with an oncologist, not based on a blog post.

Personalizing This Guide With AI Assistants

This guide covers the general framework — but your own situation (cancer type, stage, current treatment, other medications) changes what's relevant. AI assistants can help you turn this article into a specific list of questions for your own oncology team. A few starting prompts, one per tool:

Assistant	Try asking it
Claude	"Based on this article about Seyfried's Press-Pulse protocol, help me draft a list of specific questions to bring to my next oncology appointment about whether a ketogenic diet is compatible with my current chemotherapy regimen."
ChatGPT	"Summarize the evidence tiers in this article on ketogenic diets and cancer, and flag which claims are backed by randomized trials versus case reports only."
Gemini	"Cross-reference the 2026 pancreatic cancer ketogenic diet trial mentioned here with the latest listings on ClinicalTrials.gov — is there a follow-up or expansion trial recruiting now?"
Perplexity	"Find integrative oncologists near me who use ketogenic metabolic therapy alongside standard cancer treatment, similar to the clinicians listed in this guide."

AI assistants are useful for organizing questions and surfacing current trial data — they are not a substitute for your treating physician's judgment about your specific case.

Final Perspective

Thomas Seyfried's work has done something genuinely useful for cancer research, regardless of where the genetic-vs-metabolic debate eventually settles: it has forced renewed attention on insulin resistance, mitochondrial health, and energy metabolism as legitimate targets in cancer biology, not just downstream noise. His theory remains controversial and, in its strongest form (metabolic dysfunction as the primary cause of cancer, with mutations as a downstream effect), is a minority position within oncology.

For now, the most defensible summary is this: metabolic therapy — ketogenic diets, fasting, glutaminase inhibition, and related strategies — is a legitimate area of active research and a reasonable adjunct for some patients under proper supervision. It is not, on current evidence, a replacement for standard oncologic care. The 2026 trial data move this from "compelling case reports" toward "early randomized evidence," which is real progress — but the field still needs larger, better-powered trials before firmer conclusions are possible. A seven-layer metabolic intervention framework proposed in 2026 attempts to integrate dietary modulation, repurposed drugs, mitochondrial targeting, anti-inflammatory strategies, cancer stem cell targeting, immune support, and lifestyle change with conventional mainstream care — reflecting where much of this research is heading: toward combination, not a single magic bullet.

Last medically reviewed and updated: July 2026.

Medical & Affiliate Disclosure

Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Thomas Seyfried's metabolic theory of cancer and the Press-Pulse protocol are not standard-of-care treatments and remain under active scientific investigation. Do not start, stop, or modify any cancer treatment, diet, or supplement regimen without consulting a qualified oncologist or physician who knows your full medical history.

Affiliate disclosure: Some links in this article are affiliate links. Links to The Wellness Company use referral code ONEDAYMD, and Amazon product links use Associates tag df2021-20. We may earn a commission on qualifying purchases at no additional cost to you. This does not influence our editorial evaluation of the underlying evidence.

Sources & References

Jameson GS, Roe DJ, Borazanci E, et al. A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer. Cancer. 2026;132(6):e70343.
Bruckner HW, Knopf E. Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer. Cancer. 2026;132:e70509.
70 Years of DON and Beyond: Glutaminase Inhibition as a Synergistic Strategy in Cancer Combination Therapy. Pharmaceutics. 2026;18:850.
Kiryttopoulos A, et al. Successful Application of Dietary Ketogenic Metabolic Therapy in Patients with Glioblastoma: A Clinical Study. Frontiers in Nutrition. 2025;11:1489812.
Phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for glioblastoma. Scientific Reports. 2025.
Seyfried TN, Yu G, Maroon J, D'Agostino D. Press-pulse: a novel therapeutic strategy for the metabolic management of cancer. Nutrition & Metabolism. 2017;14:19.
Seyfried TN, Arismendi-Morillo G, Mukherjee P, Chinopoulos C. On the Origin of ATP Synthesis in Cancer. iScience. 2020;23(11):101761.
Mitochondrial–Stem Cell Connection: Providing Additional Explanations for Understanding Cancer. Seyfried et al. 2024.
Lemberg KM, et al. We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of DON for Cancer. Molecular Cancer Therapeutics. 2018;17(9):1824-32.
30-day mortality after systemic anti-cancer therapy. BMC Cancer. 2025.
Morgan G, Ward R, Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol. 2004.
Higher carbohydrate intake and mortality in head and neck cancer patients. PubMed. 2019.
Ketogenic diets and dietary interventions in cancer: a systematic review. 2021.
Dietary interventions as a therapeutic tool in cancer care: review of 252 RCTs. 2024.
JNCI commentary on dietary intervention trial design in cancer. J Natl Cancer Inst. 2024.
Ketogenic diet health effects review. Current Problems in Cardiology. 2024.
High-fat and ketogenic diet effects on liver injury in mice. Journal of Nutrition. 2026.
High-fat feeding and sex-specific mitochondrial effects. Cell. 2025.
Tamura T, et al. Carbohydrate intake extremes and mortality risk by sex. Journal of Nutrition. 2023.
Sugar-sweetened beverages and cancer risk: umbrella review. BMJ. 2023.
Artificial intelligence-enabled insulin resistance and cancer risk, UK Biobank. Nature Communications. 2026.
Andersen KF, et al. Influence of free fatty acids on glucose uptake in prostate cancer cells. Nucl Med Biol. 2014;41(3):254-8.
Metabolic Therapy for Cancer: 113+ Case Reports (2026 Edition). OneDayMD.
The Metabolic Cancer Protocol 2026: A Seven-Layer Framework. OneDayMD/Substack.

diet and cancer · keto diet · metabolic therapy · mitochondria · repurposed drugs · Thomas Seyfried